Effectiveness of Clinical Decision Support Based Intervention in the Improvement of Care for Adult Sickle Cell Disease Patients in Primary Care

References

1. 1.↵
   1. Quinn CT,
   2. Rogers ZR,
   3. McCavit TL,
   4. et al

   . Improved survival of children and adolescents with sickle cell disease. Blood 2010;115:3447–52.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Paulukonis ST,
   2. Eckman JR,
   3. Snyder AB,
   4. et al

   . Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008. Public Health Rep 2016;131:367–75.

   OpenUrlCrossRef
3. 3.↵
   1. Brousseau DC,
   2. Owens PL,
   3. Mosso AL,
   4. et al

   . Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010;303:1288–94.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Hunt SE,
   2. Sharma N

   . Transition from pediatric to adult care for patients with sickle cell disease. JAMA 2010;304:408–9; author reply 409.

   OpenUrlCrossRef
5. 5.↵
   1. Yawn BP,
   2. Buchanan GR,
   3. Afenyi-Annan AN,
   4. et al

   . Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312:1033–48.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Blinder MA,
   2. Vekeman F,
   3. Sasane M,
   4. et al

   . Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer 2013;60:828–35.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Puliyel M,
   2. Mainous AG 3rd.,
   3. Berdoukas V,
   4. et al

   . Iron toxicity and its possible association with treatment of Cancer: Lessons from hemoglobinopathies and rare, transfusion-dependent anemias. Free Radic Biol Med 2015;79:343–51.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Darbari DS,
   2. Kple-Faget P,
   3. Kwagyan J,
   4. et al

   . Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006;81:858–63.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Mainous AG 3rd.,
   2. Gill JM,
   3. Carek PJ

   . Elevated serum transferrin saturation and mortality. Ann Fam Med 2004;2:133–8.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Ward R

    . An update on disordered iron metabolism and iron overload. Hematology 2010;15:31131–7.

    OpenUrl
11. 11.↵
    1. Mainous AG 3rd.,
    2. Wright RU,
    3. Hulihan MM,
    4. et al

    . Elevated transferrin saturation, health-related quality of life and telomere length. Biometals 2014;27:135–41.

    OpenUrl
12. 12.↵
    1. Mehta SR,
    2. Afenyi-Annan A,
    3. Byrns PJ,
    4. et al

    . Opportunities to improve outcomes in sickle cell disease. Am Fam Physician 2006;74:303–10.

    OpenUrlPubMedWeb of Science
13. 13.↵
    1. Sobota A,
    2. Neufeld EJ,
    3. Sprinz P,
    4. et al

    . Transition from pediatric to adult care for sickle cell disease: Results of a survey of pediatric providers. Am J Hematol 2011;86:512–5.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Mainous AG 3rd.,
    2. Tanner RJ,
    3. Harle CA,
    4. et al

    . Attitudes toward management of sickle cell disease and its complications: A national survey of academic family physicians. Anemia 2015;2015:853835.

    OpenUrl
15. 15.↵
    1. Peterson LE,
    2. Blackburn B,
    3. Phillips RL Jr.,
    4. et al

    . Family medicine department chairs' opinions regarding scope of practice. Academic Med 2015;90:1691–7.

    OpenUrlPubMed